An ACR delegation will propose two new resolutions on issues affecting practicing rheumatologists and their patients at the American Medical Association Interim Meeting of the House of Delegates in Honolulu Nov. 11–14. These proposals promote transparency of pharmacy benefit manager (PBM) practices and the protection of private payer consultation codes. Resolution 810 The ACR is…
Search results for: pharmacy benefit managers
Rheumatology Champions Call for Lower Prescription Drug Costs, and More in Meeting with Congressional Legislators
ACR advocates recently returned to Capitol Hill to meet with members of Congress as part of the Advocates for Arthritis fly-in conference on Sept. 26. This annual event brings together rheumatology professionals to advocate on behalf of the rheumatology community. Core issues on which the advocates focused this year include lowering the out-of-pocket cost of…
What Price Glory (or, at Least, Getting Your Foot in the Door)?
In many respects, this is the beginning of the golden age of rheumatology. Diagnostic and therapeutic approaches are now available that have radically altered for the better the lives of people with diseases that were considered virtually untreatable just a few years ago. The rheumatologist’s approach to patients with rheumatoid arthritis, the spondyloarthropathies, osteoporosis and…
Rheumatology Advocates Visit D.C. to Act for Arthritis
The ACR/ARHP’s annual fly-in to D.C. (#Act4Arthritis) was a huge success. More than 100 ACR/ARHP members and patients from across the nation attended meetings on Capitol Hill to advocate for people living with rheumatic diseases. In all, our advocates visited 138 Senate and House offices. This year’s fly-in on Sept. 25–26 coincided with the second-annual…
U.S. Senator Reveals Results of Opioid Inquiry into Insys
BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…
Help the ACR Bring Its Message to the Hill
The ACR will be back on Capitol Hill Sept. 26 to advocate for lower out-of-pocket costs of prescription drugs and the repeal of arbitrary Medicare therapy caps, as well as to shed light on the role of pharmacy benefit managers (PBMs) in drug pricing. But it will take the voice of all rheumatology professionals and…
ATAP Holds Inaugural In-Person Meeting
The ACR recently announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the role pharmacy benefit managers (PBMs) play in driving up drug costs. The inaugural ATAP in-person meeting wrapped up on July 19 in Washington, D.C. The Alliance currently consists of the…
ACR Pushes for Patient Interests, Against Spending Cuts
Greetings from Washington, D.C. Your advocacy team had another busy month. Unlike my prior updates, and in order to keep our focus on health policy, I avoid mentioning anything about Washington investigations into obstruction of justice, collusion, etc. You get enough of that elsewhere. The Healthcare Bill Obamacare repeal and reform efforts are speeding up….
ACR Offers Hands-On 101 Course in Advocacy
The ACR’s Advocacy 101 course will be held Sept. 24 in Washington, D.C. The course is an interactive, intensive, full-day opportunity for fellows in training and program directors to learn about and become inspired to advocate for the continued strength of rheumatology recruitment and support for education, research and clinical practice. Course applications will be…
The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology
Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »